Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease
Open Access
- 1 February 2000
- journal article
- clinical trial
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 14 (2) , 171-176
Abstract
Background: Mycophenolate mofetil (MMF) is a new immunosuppressant with pharmacodynamic properties comparable to azathioprine. Recent reports found MMF to be effective in inflammatory bowel disease (IBD).Methods: An open‐label prospective and uncontrolled multicentre 6 month trial of MMF in combination with steroids was conducted in 24 chronic active IBD patients. A daily steroid demand of ≥ 10 mg prednisone in the preceding 2 months and a Crohn’s disease activity index (CDAI) > 150, or moderate to severe activity according to Truelove, served as criteria for chronic activity. The treatment consisted of a steroid pulse and tapering protocol in combination with MMF 2 g/day. A prednisone dose of 5 mg/day was maintained during months 4–6. The primary end‐point was induction and maintenance of remission.Results: Only 10 of 24 patients had achieved remission after 3 months. All but one Crohn’s disease patient had relapsed by the end of the study at 6 months. Depression and migraine necessitated drug withdrawal in two patients.Conclusion: In conclusion, MMF 2 g/day was unable to induce and maintain remission for a period of 6 months in 23 of 24 chronic active IBD patients. Further controlled investigations are required in view of recent conflicting reports.Keywords
This publication has 18 references indexed in Scilit:
- The role of mycophenolate mofeltil in the management of refractory inflammatory bowel disease (IBD)Gastroenterology, 1998
- Mycophenolate mofetil reduces tissue damage in an experimental model of colitis in ratsGastroenterology, 1998
- A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1Transplantation, 1996
- Mycophenolate MofetilDrugs, 1996
- MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN PRIMARY CADAVERIC RENAL ALLOGRAFT RECIPIENTSTransplantation, 1995
- INHIBITION OF BOTH MLC AND IN VITRO IgG MEMORY RESPONSE TO TETANUS TOXOID BY RS-61443Transplantation, 1991
- Lymphocyte‐Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide DepletionScandinavian Journal of Immunology, 1991
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- Mycophenolic acid for psoriasisJournal of the American Academy of Dermatology, 1987
- Cortisone in Ulcerative ColitisBMJ, 1955